Immuneering Corporation (IMRX)
Immuneering Statistics
Share Statistics
Immuneering has 35.89M shares outstanding. The number of shares has increased by 21.02% in one year.
Shares Outstanding | 35.89M |
Shares Change (YoY) | 21.02% |
Shares Change (QoQ) | 15.58% |
Owned by Institutions (%) | 14.42% |
Shares Floating | 25.89M |
Failed to Deliver (FTD) Shares | 3.84K |
FTD / Avg. Volume | 0.22% |
Short Selling Information
The latest short interest is 2.05M, so 6.59% of the outstanding shares have been sold short.
Short Interest | 2.05M |
Short % of Shares Out | 6.59% |
Short % of Float | 9.13% |
Short Ratio (days to cover) | 1.19 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -1.18. Immuneering's PEG ratio is 0.
PE Ratio | 0 |
Forward PE | -1.18 |
PS Ratio | 0 |
Forward PS | 0.2 |
PB Ratio | 0 |
P/FCF Ratio | -1.2 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Immuneering.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.28, with a Debt / Equity ratio of 0.1.
Current Ratio | 5.28 |
Quick Ratio | 5.28 |
Debt / Equity | 0.1 |
Debt / EBITDA | -0.06 |
Debt / FCF | -75.57 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-924.8M |
Employee Count | 66 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -36.17% in the last 52 weeks. The beta is -0.26, so Immuneering's price volatility has been lower than the market average.
Beta | -0.26 |
52-Week Price Change | -36.17% |
50-Day Moving Average | 1.72 |
200-Day Moving Average | 1.76 |
Relative Strength Index (RSI) | 40.01 |
Average Volume (20 Days) | 1.77M |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -64.07B |
Net Income | -61.04B |
EBITDA | -64.07B |
EBIT | n/a |
Earnings Per Share (EPS) | -2035.8 |
Balance Sheet
The company has 36.14B in cash and 4.16B in debt, giving a net cash position of 31.98B.
Cash & Cash Equivalents | 36.14B |
Total Debt | 4.16B |
Net Cash | 31.98B |
Retained Earnings | -224.3B |
Total Assets | 52.71M |
Working Capital | 32.08M |
Cash Flow
In the last 12 months, operating cash flow was -55M and capital expenditures -84.88K, giving a free cash flow of -55.08M.
Operating Cash Flow | -55M |
Capital Expenditures | -84.88K |
Free Cash Flow | -55.08M |
FCF Per Share | -1.84 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
IMRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for IMRX is $12.5, which is 733.3% higher than the current price. The consensus rating is "Buy".
Price Target | $12.5 |
Price Target Difference | 733.3% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Scores
Altman Z-Score | -6.35 |
Piotroski F-Score | 2 |